Trial Search Results

Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 Diabetes

This study is a single-arm, multi-center, Home and Hotel Clinical Investigation in pediatric subjects with type 1 diabetes on insulin pump therapy. The purpose of this study is to demonstrate that the closed loop algorithm is safe as part of the overall system, and to assess the PLGM feature in 7-13 years old subjects.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Medtronic Diabetes

Stanford Investigator(s):

Intervention(s):

  • Device: Insulin Pump

Phase:

N/A

Eligibility


Inclusion Criteria:

General Inclusion Criteria

   1. Subject is age 2-13 years at time of screening

   2. Subject has a clinical diagnosis of type 1 diabetes for 1 year or more as determined
   via medical record or source documentation by an individual qualified to make a
   medical diagnosis

   3. Subject age 2-6 years has a clinical diagnosis of type 1 diabetes for 3 months or more
   as determined via medical record or source documentation by an individual qualified to
   make a medical diagnosis

   Study-specific inclusion criteria

   4. Subject must have a minimum daily insulin requirement (Total Daily Dose) of greater
   than or equal to 8 units

   5. Subjects 7-13: Subjects and their parent(s)/guardian(s) are willing to participate in
   an overnight visit at the end of the run-in period.

   6. Subject 7-13 years of age and their parent(s)/guardian(s) are willing to participate
   in a hotel study for the specified duration of hotel stay.

   7. Subject 2-6 years of age and their parent(s)/guardian(s) are willing to participate in
   an extended visit during the study period to perform Frequent Sample Testing.

   8. Subject must have companion 18 years or older who will sleep in the same dwelling
   place every night during the study period. This requirement may be verified by subject
   report at screening visit.

   9. Subject is willing to perform ≥ 4 finger stick blood glucose measurements daily

10. Subject is willing to perform required sensor calibrations

11. Subject is willing to wear the system continuously throughout the study

12. Subject has a Glycosylated hemoglobin (A1C) value less than 10.0% (as processed by
   Central Lab) at time of screening visit Note: All HbA1C blood specimens will be sent
   to and tested by a NGSP certified Central Laboratory. A1C testing must follow National
   Glycohemoglobin Standardization Program (NGSP) standards.

13. Subject has TSH in the normal range OR if the TSH is out of normal reference range the
   Free T3 is below or within the lab's reference range and Free T4 is within the normal
   reference range.

14. Subject 7 -13 years of age has had pump therapy for greater than 6 months prior to
   screening (with or without CGM experience)

15. Subject 2-6 years of age has had pump therapy for greater than 90 days prior to
   screening (with or without CGM experience)

16. Subjects and their parent(s)/guardian(s) are willing to upload data from the study
   pump; must have Internet access and a computer system that meets the requirements for
   uploading the study pump

17. If subject has celiac disease, it has been adequately treated as determined by the
   investigator

18. Subjects and their parent(s)/guardian(s) are willing to take one of the following
   insulins and can financially support the use of either of the 2 insulin preparations
   throughout the course of the study (i.e. co-payments for insulin with insurance or
   able to pay full amount)

      - Humalog® (insulin lispro injection)

      - NovoLog® (insulin aspart)

19. Subjects and their parent(s)/guardian(s)/companions must be able to speak and be
   literate in English as verified by the investigator

Exclusion Criteria:

   1. Subject has a history of 2 or more episodes of severe hypoglycemia, which resulted in
   any the following during the 6 months prior to screening:

      1. Medical assistance (i.e. Paramedics, Emergency Room ( ER) or Hospitalization)

      2. Coma

      3. Seizures

   2. Subject is unable to tolerate tape adhesive in the area of sensor placement

   3. Subject has any unresolved adverse skin condition in the area of sensor placement
   (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection)

   4. Females who are sexually active and able to conceive will be excluded if they are not
   using an effective method of contraception and do not agree to continue using an
   effective method of contraception for the duration of the study as determined by
   investigator.

   5. Subject has a cardiovascular condition which the investigator determines should
   exclude the subject, i.e. ventricular rhythm disturbance, hypertrophic cardiomyopathy

   6. Subject is being treated for hyperthyroidism at time of screening

   7. Subject has diagnosis of adrenal insufficiency

   8. Subject 7-13 years of age has had DKA in the 6 months prior to screening visit.

   9. Subject 2-6 years of age has had DKA in the 3 months prior to screening visit

10. Subject has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8
   weeks from time of screening visit, or plans to take any oral, injectable, or IV
   glucocorticoids during the course of the study

11. Subject is actively participating in an investigational study (drug or device) wherein
   he/she has received treatment from an investigational study drug or investigational
   study device in the last 2 weeks

12. Subject 7-13 years of age has been hospitalized or has visited the ER in the 6 months
   prior to screening resulting in a primary diagnosis of uncontrolled diabetes

13. Subject 2-6 years of age has been hospitalized or has visited the ER in the 3 months
   prior to screening resulting in a primary diagnosis of uncontrolled diabetes

14. Subject is currently abusing illicit drugs

15. Subject is currently abusing marijuana.

16. Subject is currently abusing prescription drugs

17. Subject is currently abusing alcohol

18. Subject is using pramlintide (Symlin), DPP-4 inhibitor, liraglutide (Victoza or other
   GLP-1 agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time
   of screening

19. Subject has a history of visual impairment which would not allow subject to
   participate in the study and perform all study procedures safely, as determined by the
   investigator

20. Subject has elective surgery planned that requires general anesthesia during the
   course of the study

21. Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell
   transfusion or erythropoietin within 3 months prior to time of screening

22. Subject plans to receive red blood cell transfusion or erythropoietin over the course
   of study participation

23. Subject diagnosed with current eating disorder such as anorexia or bulimia

24. Subject has been diagnosed with chronic kidney disease that results in chronic anemia

25. Subject has a hematocrit that is below the normal reference range of lab used.

26. Subject is on dialysis

27. Subject has serum creatinine of >2 mg/dL.

Ages Eligible for Study

2 Years - 13 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Suzette Reuschel-Virgilio
650-725-3950
Recruiting